Previous close | 87.03 |
Open | 87.52 |
Bid | 87.96 x 1100 |
Ask | 88.07 x 800 |
Day's range | 85.61 - 88.10 |
52-week range | 55.25 - 159.89 |
Volume | |
Avg. volume | 1,557,790 |
Market cap | 8.205B |
Beta (5Y monthly) | 1.01 |
PE ratio (TTM) | N/A |
EPS (TTM) | -7.80 |
Earnings date | 26 Feb 2024 - 01 Mar 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 140.28 |
Sarepta Therapeutics (NASDAQ: SRPT) is a mid-cap stock that has the potential to be a big player in the gene therapy market -- at least, so the business and its investors hope. It has made for a volatile investment in recent years, but with a possible game-changing treatment in its portfolio, there may be a ton of upside for Sarepta in the long run. With over 40 programs currently in development, Sarepta is hopeful it can become a leading genetic medicine company one day.
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.